Learn what Wall Street already knows in our "Billion Dollar Secret" guide.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Sales Slip at McKesson
McKesson Corporation’s ( MCK - Analyst Report) second quarter fiscal 2013 (ended September 30, 2012) adjusted earnings of $1.92 per share surpassed the Zacks Consensus Estimate of $1.76 per share. Also, the reported quarter’s adjusted earnings spiked 18% from the year-ago period. Earnings benefited from a lower share count.
Revenues declined 1% to $29.9 billion. Revenues were short of the Zacks Consensus Estimate of $30.9 billion. Quarter in Detail
McKesson operates through two segments: Distribution Solutions and Technology Solutions.
Revenues at the Distribution Solutions segment decreased 1% to $29 billion in the reported quarter. The decline was attributable to lower sales in the US pharmaceutical distribution unit.
Revenues from the US pharmaceutical distribution business came in at $25.7 billion, down 1%. The decline was due to brand-to-generic conversions and one less sales day.
Canadian revenue decreased 5% to $2.4 billion. The decrease was attributable to unfavorable foreign exchange movements. Revenues from Medical-Surgical distribution and services came in flat at $873 million. Sales of the sub-group were impacted by fewer sales days in the quarter.
Revenues at the Technology Solutions segment came in flat at $824 million. Operating expenses climbed 1.9% in the reported quarter to $1.1 billion. Fiscal 2013 Outlook
The company tweaked its adjusted earnings outlook for fiscal 2013. McKesson expects earnings (excluding special items) in the range of $7.15-$7.35 per share (previous projection: $7.05 - $7.35 share). The Zacks Consensus Estimate for fiscal 2013 currently stands at $7.26 per share. McKesson to Buy PSS World
In a bid to expand its product portfolio, McKesson inked a deal to buy PSS World Medical, Inc. for $29.00 per share in cash. The total value of the deal, in which McKesson will assume PSS World Medical’s debt, is estimated at approximately $2.1 billion. McKesson expects to generate more than $100 million in annual savings (pre-tax) by the fourth year after the closure of the deal. Neutral on McKesson
We currently have a Neutral recommendation on McKesson. The stock carries a Zacks #3 Rank (Hold rating) in the short run.